Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Exploring the cellular basis of human disease through a large-scale mapping of deleterious genes to cell types

Cornish AJ., Filippis I., David A., Sternberg MJ.

Clinical Trial on Neuroinflammation, published in Genome Med (2015) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Genome Med (2015)
Reported sample size
—
Source database
Europe PMC
PMID
26330083
PMCID
PMC4557825
DOI
10.1186/s13073-015-0212-9
Citations
8

Abstract (original English)

Background Each cell type found within the human body performs a diverse and unique set of functions, the disruption of which can lead to disease. However, there currently exists no systematic mapping between cell types and the diseases they can cause. Methods In this study, we integrate protein-protein interaction data with high-quality cell-type-specific gene expression data from the FANTOM5 project to build the largest collection of cell-type-specific interactomes created to date. We develop a novel method, called gene set compactness (GSC), that contrasts the relative positions of disease-associated genes across 73 cell-type-specific interactomes to map genes associated with 196 diseases to the cell types they affect. We conduct text-mining of the PubMed database to produce an independent resource of disease-associated cell types, which we use to validate our method. Results The GSC method successfully identifies known disease-cell-type associations, as well as highlighting associations that warrant further study. This includes mast cells and multiple sclerosis, a cell population currently being targeted in a multiple sclerosis phase 2 clinical trial. Furthermore, we build a cell-type-based diseasome using the cell types identified as manifesting each disease, offering insight into diseases linked through etiology. Conclusions The data set produced in this study represents

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
CellsHumansDiseaseGenetic Predisposition to DiseaseGene ExpressionPhenotypeDatabases, GeneticData MiningProtein Interaction Maps

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research